CNRMF (China Regenerative Medicine International) Risk Assessment

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CNRMF China Regenerative Medicine International Ltd CNRMF
30 GF Score
Price $0.04
GF Value $0.09
! 5 Warning Signs
View Full Analysis

What is China Regenerative Medicine International Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of China Regenerative Medicine International is: No Data: Cannot be evaluated.

China Regenerative Medicine International  (OTCPK:CNRMF) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

China Regenerative Medicine International Risk Assessment Related Terms

CNRMF vs VRTX, REGN, RVMD: Risk Assessment Comparison

For the Biotechnology subindustry, China Regenerative Medicine International's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

China Regenerative Medicine International Risk Assessment vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, China Regenerative Medicine International's Risk Assessment distribution charts can be found below:

* The bar in red indicates where China Regenerative Medicine International's Risk Assessment falls into.


CNRMF
30GF Score
China Regenerative Medicine International Ltd CNRMF
Risk Assessment is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is China Regenerative Medicine International (CNRMF) Overvalued in 2026?

Based on GuruFocus' analysis, China Regenerative Medicine International stock appears to be undervalued. The current stock price of $0.04 is trading 61.1% below its estimated GF Value™ of $0.09.

Key valuation signals for CNRMF:

  • Risk Assessment:
  • GF Value™: $0.09 vs. price of $0.04 (61.1% below fair value)
  • GF Score™: 30/100 with 5 warning signs

No single metric tells the full story. See the CNRMF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

China Regenerative Medicine International Business Description

Other Exchanges 08158:Hong Kong
Address 132 Nathan Road, Suite 2310-2318, Miramar Tower, Tsim Sha Tsui, Kowloon, HKG
China Regenerative Medicine International Ltd is an investment holding company. The company is engaged in the provision of healthcare products and services. It is engaged in research and development, production and sales of tissue engineering and regenerative medicine products. The business scope of company includes tissue engineering, cosmetics, cell storage, preparation and therapy, hospitals administration and other business division. The segments of the company are Aesthetic medical and beauty services and Medical services. The majority of the company's revenue is derived from its Aesthetic medical and beauty services segment that provides medical beauty products and services. Geographically, the Hong Kong accounts for the majority of the revenue and also has a presence in PRC.
30GF Score

Get the complete analysis for CNRMF

Risk Assessment is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.04
Price
$0.09
GF Value